{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T08:17:37Z","timestamp":1780647457027,"version":"3.54.1"},"reference-count":80,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am Soc Clin Oncol Educ Book"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:p> Gastroesophageal (GE) and pancreatobiliary (PB) cancers represent a significant clinical challenge. In this context, it is critical to understand the key molecular targets within these malignancies including how they are assayed for as well as the clinical actionability of these targets. Integrating biomarkers into the standard of care presents a critical avenue for refining treatment paradigms. This review aims to explore these complexities, offering insights into the optimal sequencing of chemotherapy and targeted therapies and their utility in the management of GE and PB cancers. The timely integration of promising investigational therapies into clinical practice has broader implications around strategies for future clinical trial designs, which would pave the way for advancements in the management of GE and PB cancers. This review provides guidance in navigating the evolving landscape of GE and PB cancer care, which ultimately will drive forward progress in the field and lead to improved patient outcomes. <\/jats:p>","DOI":"10.1200\/edbk_433640","type":"journal-article","created":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T15:59:18Z","timestamp":1718726358000},"source":"Crossref","is-referenced-by-count":2,"title":["Incorporating Molecular Data Into Treatment Decision Making in Gastroesophageal and Pancreaticobiliary Cancers: Timing and Strategies"],"prefix":"10.1200","volume":"44","author":[{"given":"Andrew","family":"Hall","sequence":"first","affiliation":[{"name":"Leeds Cancer Research UK Clinical Trials Unit, University of Leeds, Leeds, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah R.","family":"Brown","sequence":"additional","affiliation":[{"name":"Leeds Cancer Research UK Clinical Trials Unit, University of Leeds, Leeds, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niharika B.","family":"Mettu","sequence":"additional","affiliation":[{"name":"Department of Medicine, Duke University Medical Center, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul C.","family":"Miller","sequence":"additional","affiliation":[{"name":"Oxford NIHR Biomedical Research Centre, Churchill Hospital, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth C.","family":"Smyth","sequence":"additional","affiliation":[{"name":"Oxford NIHR Biomedical Research Centre, Churchill Hospital, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3971-2964","authenticated-orcid":true,"given":"Andrew B.","family":"Nixon","sequence":"additional","affiliation":[{"name":"Department of Medicine, Duke University Medical Center, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"bibr1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-321600"},{"key":"bibr2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04161-3"},{"key":"bibr3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02033-0"},{"key":"bibr4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2004413"},{"key":"bibr5","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00215-2"},{"key":"bibr6","volume-title":"Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)","year":"2021"},{"key":"bibr7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00620-7"},{"key":"bibr8","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02465-7"},{"key":"bibr9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00797-2"},{"key":"bibr10","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00541-7"},{"key":"bibr11","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2022-0093"},{"key":"bibr12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00686"},{"key":"bibr13","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13112839"},{"key":"bibr14","volume-title":"TremelImumab aNd Durvalumab for the Non-operatIve Management (NOM) of MSI-High Resectable GC\/GEJC. (INFINITY)","year":"2023"},{"key":"bibr15","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-2264(199709)20:1<38::AID-GCC6>3.0.CO;2-A"},{"key":"bibr16","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1210477"},{"key":"bibr17","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2016-0331-CP"},{"key":"bibr18","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61121-X"},{"key":"bibr19","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30481-9"},{"key":"bibr20","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30111-0"},{"key":"bibr21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.53.6136"},{"key":"bibr22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03077"},{"key":"bibr24","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.04.020"},{"key":"bibr25","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00718-X"},{"key":"bibr26","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-1547"},{"key":"bibr27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04907-0"},{"key":"bibr28","doi-asserted-by":"publisher","DOI":"10.1016\/j.labinv.2023.100284"},{"key":"bibr29","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1523096"},{"key":"bibr30","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.36_suppl.434420"},{"key":"bibr31","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01800-8"},{"key":"bibr32","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(24)00043-8"},{"key":"bibr33","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2023.100154"},{"key":"bibr34","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.3_suppl.306"},{"key":"bibr35","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.3370"},{"key":"bibr36","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.06.012"},{"key":"bibr37","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01124"},{"key":"bibr38","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00975"},{"key":"bibr39","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200015"},{"key":"bibr40","doi-asserted-by":"publisher","DOI":"10.1093\/bjs\/znab410"},{"key":"bibr41","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-13-0050"},{"key":"bibr42","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21186856"},{"key":"bibr43","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30109-1"},{"key":"bibr44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206834"},{"key":"bibr45","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30157-1"},{"key":"bibr46","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903387"},{"key":"bibr47","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00003"},{"key":"bibr48","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-0814-x"},{"key":"bibr49","author":"Wintheiser G","journal-title":"JCO Precis Oncol"},{"key":"bibr50","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2117344"},{"key":"bibr51","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.3836"},{"key":"bibr52","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30254"},{"key":"bibr53","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0078"},{"key":"bibr54","doi-asserted-by":"publisher","DOI":"10.1159\/000511919"},{"key":"bibr55","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-016-9645-x"},{"key":"bibr56","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00336-3"},{"key":"bibr57","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00242-5"},{"key":"bibr58","doi-asserted-by":"publisher","DOI":"10.3390\/cells12162098"},{"key":"bibr59","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0908721"},{"key":"bibr60","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33013"},{"key":"bibr61","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_238977"},{"key":"bibr62","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.5546"},{"key":"bibr63","doi-asserted-by":"publisher","DOI":"10.1038\/gim.2014.153"},{"key":"bibr64","doi-asserted-by":"publisher","DOI":"10.4251\/wjgo.v14.i7.1252"},{"key":"bibr65","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1136227"},{"key":"bibr66","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000001583"},{"key":"bibr67","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12165394"},{"key":"bibr68","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-023-01491-9"},{"key":"bibr69","volume":"41","author":"Park W","year":"2023","journal-title":"J Clin Oncol"},{"key":"bibr70","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100762"},{"key":"bibr71","doi-asserted-by":"publisher","DOI":"10.1016\/j.molonc.2015.02.011"},{"key":"bibr72","volume-title":"Master Protocols for Drug and Biological Product Development, Guidance for Industry, Draft Guidance.","author":"FDA","year":"2023"},{"key":"bibr73","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2020.05.010"},{"key":"bibr74","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1510062"},{"key":"bibr75","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-0442"},{"key":"bibr76","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2481-8"},{"key":"bibr77","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.04.341"},{"key":"bibr78","volume-title":"Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-Oncology Combinations (NEOASIS)","author":"National Cancer Institute","year":"2024"},{"key":"bibr79","doi-asserted-by":"publisher","DOI":"10.1016\/j.molonc.2014.09.011"},{"key":"bibr80","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy263"},{"key":"bibr81","volume-title":"Personalized Medicine for Advanced Biliary Cancer Patients (SAFIR-ABC10)","author":"Centre CRUUCT","year":"2022"}],"container-title":["American Society of Clinical Oncology Educational Book"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/EDBK_433640","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T16:20:00Z","timestamp":1718727600000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/EDBK_433640"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":80,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["10.1200\/EDBK_433640"],"URL":"https:\/\/doi.org\/10.1200\/edbk_433640","relation":{},"ISSN":["1548-8748","1548-8756"],"issn-type":[{"value":"1548-8748","type":"print"},{"value":"1548-8756","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6]]},"article-number":"e433640"}}